The emergence of Retatrutide ZPHC, at a strength of 120mg, is sparking considerable buzz within the medical community. This novel dual GIP and GLP-1 target medication seems to offer significant improvements in weight reduction compared to previous therapies. Initial research data have shown substantial declines in weight , potentially marking a new